enamel matrix proteins
Biologicalexperimental
In dentistry, enamel matrix derivative (EMD) is an extract of porcine fetal tooth material used to biomimetically stimulate the soft and hard tissues surrounding teeth to regrow following tissue destruction. — Wikipedia
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
2
Earliest trial started Feb 1, 2016 (NCT03025204)
Timeline
No events for the selected filters.
Indications
Approved for
Mechanism of action
- Amelogenin, X isoformTissue restoration
AMELX tissue restoration
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaEnamel matrix derivative ↗
Also known as
- emdogain
- emdogain
- enamel matrix proteins
- enamel matrix proteins
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06250088 | Phase 4 | Mar 12, 2024 | Universidad Complutense de Madrid |
| NCT07230522 | N/A | Mar 12, 2024 | Medical University of Sofia |
| NCT03025204 | Phase 4 | Feb 1, 2016 | Faculdade de Odontologia de Piracicaba, University of Campinas |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Faculdade de Odontologia de Piracicaba | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Medical University of Sofia | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Universidad Complutense de Madrid | Academic/Hospital | 1 | 1 | 1 | 2024 |
| University of Campinas | Academic/Hospital | 1 | 1 | 1 | 2016 |
4 organizations
Page 1 / 1